Last reviewed · How we verify
NCT04022603
Impact of High-level Oxygen Therapy on the Reconditioning of Type I Hypoxemic Respiratory Insufficiency Patients in Intensive Care
NA trial testing Cyclometer Ergometer in Hypoxemic Respiratory Failure in 30 participants. Completed in 3 August 2020.
3 August 2020
Quick facts
| Lead sponsor | Dr David DE BELS |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 18 August 2017 |
| Primary completion | 3 August 2020 |
| Estimated completion | 3 August 2020 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Cyclometer Ergometer
Conditions studied
- Hypoxemic Respiratory Failure — all drugs for Hypoxemic Respiratory Failure →
Sponsor
Dr David DE BELS
Who can join
18 and older, any sex, with Hypoxemic Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
High-throughput oxygen therapy is known as an alternative to non-invasive ventilation, with a benefit in terms of survival in non-hypercapnic respiratory failure patients. The use of high-throughput oxygen therapy is well studied in stable chronic obstructive pulmonary disease (COPD) patients and has as known effects the decrease of transcutaneous CO2 and respiratory rate, and the increase in the inspiratory/expiratory time report, in the tidal volume and in the forced expiratory volume per second. In the event of an exacerbation, high-flow oxygen therapy has shown to be beneficial in terms of increased mean airway pressure, tidal volume with a decrease in hypercapnia, and respiratory rate. The net effect on the CO2 pressure is linked to the CO2 clearance of the dead anatomical space by the high throughput. The effect can be compared with the one of non invasive ventilation in a stable COPD patient. Oxygen therapy, even in patients with non-hypoxic COPD at rest, has benefits in terms of performance and improvement of quality of life. High-throughput oxygen therapy has also shown a benefit in COPD patients in revalidation units, in terms of exercise performance and oxygenation. However, the reconditioning of critical patients in acute situations, by means of nasal goggles, has never been studied.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04022603
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypoxemic Respiratory Failure
Currently open trials in the same condition.
- NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
- NCT06521489 — Asymmetrical HFNCO vs Standard HFNCO Post Cardiac Surgery Patients · NA · active not recruiting
- NCT04938167 — Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hyp · NA · active not recruiting
Other Dr David DE BELS trials
Trials by the same sponsor.
- NCT04518969 — Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19 · NA · completed
- NCT04024007 — Determination of Citrate Clearance Used in Regional Anticoagulation of Continuous Venous Hemofiltration Circuits · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04022603 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr David DE BELS
- Last refreshed: 4 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04022603.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing